yafE Antibody

What is YAF2 and what cellular functions does it perform?

YAF2 (YY1-associated factor 2) is a ~20 kDa protein that plays several important regulatory roles in cellular function. It binds to MYC and inhibits MYC-mediated transactivation while also binding to MYCN and enhancing MYCN-dependent transcriptional activation. YAF2 increases calpain 2-mediated proteolysis of YY1 in vitro and functions as a component of the E2F6.com-1 complex, a repressive complex that methylates 'Lys-9' of histone H3, suggesting involvement in chromatin-remodeling processes . Understanding these functions is essential for researchers investigating transcriptional regulation, chromatin dynamics, and cellular proliferation pathways.

How do I select the appropriate YAF2 antibody for my research?

Selection should be based on your experimental application (WB, IP, IF), species reactivity requirements, and validation data quality. When choosing between monoclonal and polyclonal options, consider that monoclonal antibodies like EPR11020 provide higher specificity and reproducibility, while polyclonal antibodies may offer better signal amplification for low-abundance targets. Review validation data showing detection of endogenous YAF2 in relevant tissues (such as human skeletal muscle or fetal heart) and confirmation of the expected 20 kDa band size . Importantly, examine antibody performance across different validation strategies - genetic approaches using knockout/knockdown controls typically provide more reliable validation than orthogonal approaches, especially for immunofluorescence applications .

What are the optimal conditions for using YAF2 antibodies in Western blot applications?

For Western blot applications using YAF2 antibodies, optimal conditions include:

Include positive control samples such as human skeletal muscle or fetal heart lysates where YAF2 expression has been confirmed. For enhanced specificity, consider using PVDF membranes with low autofluorescence and optimize transfer conditions for low molecular weight proteins .

How can I establish reliable immunoprecipitation protocols using YAF2 antibodies?

Successful immunoprecipitation with YAF2 antibodies requires careful optimization. Begin with cell lysate preparation using non-denaturing buffers containing protease inhibitors to preserve protein-protein interactions. For YAF2 IP, protocols validated with the EPR11020 clone demonstrate effective pulldown from human skeletal muscle lysate . Use 2-5 μg of antibody per 500 μg of total protein, and include appropriate negative controls (such as 1X PBS or non-specific IgG) to assess non-specific binding. Detection should employ HRP-conjugated secondary antibodies that preferentially detect the non-reduced form of rabbit IgG to minimize heavy/light chain interference. Consider crosslinking the antibody to beads (protein A/G) to prevent antibody co-elution, especially if studying YAF2's interactions with transcription factors like MYC or components of the E2F6.com-1 complex .

What validation strategies are most reliable for confirming YAF2 antibody specificity?

Genetic validation approaches using knockout (KO) or knockdown (KD) controls provide the most rigorous confirmation of antibody specificity. While 61% of antibodies for Western blot applications are recommended by manufacturers based on orthogonal approaches, evidence shows that genetic validation strategies yield more reliable outcomes, particularly for immunofluorescence applications (80% confirmation rate vs. 38% for orthogonal methods) . A comprehensive validation protocol should include:

• CRISPR knockout cells as negative controls

• Observation of the predicted 20 kDa band size on Western blots

• Parallel testing of multiple antibody clones against the same target

• Cross-validation across multiple detection methods (WB, IP, IF when applicable)

• Tissue-specific expression pattern confirmation compared to established literature

The cost of rigorous KO-based validation (~$25,000) often exceeds commercial antibody sales revenue (<$5,000 per product), explaining why many commercial antibodies lack this gold-standard validation .

How can I troubleshoot non-specific binding when using YAF2 antibodies?

Non-specific binding with YAF2 antibodies may manifest as multiple bands on Western blots or diffuse staining in immunofluorescence. To systematically address these issues:

For definitive troubleshooting, the evidence from large-scale antibody validation studies indicates that testing antibodies using CRISPR knockout cells provides unambiguous differentiation between specific and non-specific signals . When KO cells are unavailable, secondary verification with alternate antibody clones targeting different epitopes can help confirm the authenticity of observed signals.

How can YAF2 antibodies be employed in chromatin immunoprecipitation (ChIP) studies?

While not explicitly validated for ChIP in the search results, YAF2's role in the E2F6.com-1 repressive complex that methylates histone H3 makes it a candidate for chromatin studies . For adapting YAF2 antibodies to ChIP applications:

• Begin with cross-validation using ChIP-grade antibodies against known YAF2 interactors (e.g., E2F6, MYC)

• Optimize chromatin fragmentation to 200-500bp fragments

• Use 5-10 μg of antibody per ChIP reaction (higher than typical WB concentrations)

• Include additional controls:

  • Input DNA (non-immunoprecipitated)

  • IgG negative control

  • Positive control (antibody against histone marks)

• Validate ChIP efficiency using qPCR primers targeting known or predicted binding sites

Given YAF2's function in histone modification, sequential ChIP (re-ChIP) might be particularly valuable to investigate co-occupancy with other chromatin-remodeling factors. Consider dual crosslinking with both formaldehyde and protein-specific crosslinkers to preserve protein-protein interactions during chromatin preparation .

What are the considerations for using YAF2 antibodies in studies of cancer and transcriptional regulation?

YAF2's interactions with MYC and MYCN, critical oncogenic transcription factors, position it as a potentially important player in cancer biology. When designing experiments to investigate these relationships:

• Select cell models with defined MYC/MYCN status and YAF2 expression

• Consider parallel detection of YAF2 and MYC family members to assess co-regulation

• Employ co-immunoprecipitation to confirm physical interactions in your specific model

• Use chromatin immunoprecipitation to map genomic binding sites

• Implement functional studies (siRNA/CRISPR) to assess the impact of YAF2 depletion on MYC-dependent transcriptional programs

Researchers should be aware that YAF2 exhibits context-dependent functions - inhibiting MYC-mediated transactivation while enhancing MYCN-dependent activation . This dual role necessitates careful experimental design and interpretation, particularly in neuroblastoma or other MYCN-amplified cancers where these opposing functions may have significant biological consequences.

How might the antibody validation approaches developed for neuroscience targets apply to YAF2 antibody development?

The large-scale antibody validation approach using knockout cell lines described for neuroscience targets offers a blueprint for improved YAF2 antibody validation . This approach involves:

• Generation of isogenic CRISPR knockout cell lines that express YAF2 endogenously

• Standardized testing protocols across multiple applications (WB, IP, IF)

• Side-by-side comparison of all commercially available antibodies against the same target

• Public sharing of validation data through platforms like ZENODO and the RRID Portal

Applying this systematic approach to YAF2 antibodies would address the current limitations in antibody reliability and reproducibility. Additionally, identifying cell types with significant YAF2 expression for knockout generation would be crucial for effective validation. The emphasis on genetic validation strategies would be particularly valuable as data indicates they provide more reliable characterization than orthogonal strategies (89% vs 80% confirmation for WB, and 80% vs 38% for IF) .

What potential insights could YAF2 research offer to chromatin immunoprecipitation sequencing (ChIP-seq) methodology development?

YAF2's role in the E2F6.com-1 complex that methylates histone H3 positions it uniquely for contributing to ChIP-seq methodology development . Advanced applications could include:

• Integrating YAF2 ChIP-seq with histone modification maps to correlate YAF2 binding with specific epigenetic states

• Developing dual ChIP-seq approaches to simultaneously map YAF2 and interacting partners

• Employing emerging CUT&RUN or CUT&Tag methods with YAF2 antibodies for higher resolution chromatin mapping

• Utilizing single-cell adaptations of chromatin profiling to understand cell-specific YAF2 functions

Research in this direction would benefit from carefully validated YAF2 antibodies, as the quality of ChIP-seq data is heavily dependent on antibody specificity. The principles established in large-scale antibody validation studies emphasize that genetic validation approaches should be prioritized when developing reagents for these advanced genomic applications .

How should researchers document and report YAF2 antibody usage in publications?

Proper documentation of YAF2 antibody usage in publications should follow emerging best practices in antibody reporting:

• Provide complete antibody identification information:

  • Supplier and catalog number

  • Clone designation for monoclonal antibodies (e.g., EPR11020)

  • Host species and antibody type (monoclonal/polyclonal)

  • RRID (Research Resource Identifier) when available

• Detail experimental conditions:

  • Dilution/concentration used for each application

  • Incubation conditions (time, temperature)

  • Blocking reagents and washing protocols

  • Detection methods and imaging parameters

• Include validation evidence:

  • Reference to prior validation or include new validation data

  • Specific controls used (genetic knockout, competing peptide)

  • Demonstration of expected molecular weight/localization

The YCharOS initiative and Antibody Registry demonstrate standardized approaches to antibody reporting that improve reproducibility. Using RRIDs for antibody citation enables tracking antibody performance across publications and supports community-based validation efforts .

How can researchers contribute to improving YAF2 antibody resources?

Researchers can actively contribute to improving YAF2 antibody resources through several mechanisms:

• Sharing validation data through open platforms like ZENODO or the RRID Portal Community

• Reporting both positive and negative results when testing commercial antibodies

• Generating and sharing YAF2 knockout or knockdown cell lines as validation resources

• Participating in community-based antibody testing initiatives

These contributions align with emerging practices in antibody validation communities. As demonstrated by the YCharOS project, sharing data through open platforms creates resources that "benefit the global life science community" . For YAF2 research specifically, contributing validation data across different cellular contexts would be particularly valuable given YAF2's roles in diverse processes from MYC regulation to chromatin remodeling .